UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2019

Commission File Number: 001-36582

Auris Medical Holding Ltd.

(Exact name of registrant as specified in its charter)

Clarendon House, 2 Church Street

Hamilton HM 11, Bermuda

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒       Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐      No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐      No ☒

Annual General Meeting Results

On May 8, 2019, Auris Medical Holding Ltd. (the “ Company ”) held its Annual General Meeting of Shareholders (the “ Meeting ”). The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

Agenda Item 1: Re-election of the members of the Board of Directors.

The Company’s shareholders re-elected Thomas Meyer, PhD, Armando Anido, MBA, Mats Peter Blom, MBA, Calvin W. Roberts, MD and Alain Munoz, MD, as member of the Board of Directors, each for a term of one year ending upon completion of the 2020 Annual General Meeting.

Agenda Item 2: Re-election of the Auditors

The Company’s shareholders re-elected Deloitte AG, Switzerland, as auditors of Auris Medical Holding Ltd. for the 2019 financial year.

Agenda Item 3: Compensation of the Board of Directors and the Executive Management Committee

The Company’s shareholders approved, on a non-binding advisory basis, the 2018 Board of Directors and executive officers compensation.

Other Items

At the Meeting, the Chairman informed the shareholders that going forward the Company, as a Foreign Private Issuer pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), intends to file financial reports on a semi-annual instead of a quarterly basis in compliance with such SEC rules. The next financial statements will therefore be filed for the first six months ended June 30, 2019.